AR 12456

Drug Profile

AR 12456

Latest Information Update: 01 May 1995

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Antihyperlipidaemics; Antithrombotics
  • Mechanism of Action Cyclic nucleotide phosphodiesterase inhibitors; Platelet aggregation inhibitors; Thromboxane receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Thrombosis

Most Recent Events

  • 13 Apr 1995 Discontinued-Preclinical for Atherosclerosis in Germany (Unknown route)
  • 13 Apr 1995 Discontinued-Preclinical for Thrombosis in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top